generics

Pfizer Abandons $118 billion AstraZeneca Takeover

US Court Dismisses Teva Case to Block Generic Copaxone

Actavis Sues FDA Over Generic of Pfizer’s Celebrex

AstraZeneca Plans Spin-offs and Announces Cancer Progress

India’s Sun Pharmaceutical to Buy Compatriot Ranbaxy

Teva Asks U.S. Supreme Court to Stay Copaxone Ruling

Swedish Drugmaker Meda Spurns Mylan Approach

GDUFA’s Impact on the API Industry – an Update

Novartis Ends Heart Failure Drug Tests Early on Strong Results

U.S. Justices Agree to Hear Teva's Copaxone Appeal

Novo Nordisk Sees Chance of U.S. Tresiba Launch Before Rivals

Generic Drugmakers Ramp up Campaign Against FDA Label Plan

Actavis to Buy Forest Labs for $25 billion

German Generics Producers Charge Discrimination

Fourth Ranbaxy Generics Plant Hit by FDA Ban

EU Fines Drugmakers €16 million for Painkiller Delay

Double Risk with an Upgrade

Sourcing from India and China

GlaxoSmithKline India Hit By Drop In Bulk Orders

Saltigo: 'Working Proactively With Trends'

Adaptability — A lot has happened in the world of custom manufacturing since Saltigo was carved out of Lanxess' fine chemicals business in 2006.

Enzymes as a Catalytic All Rounder

Agrochemical’s Role in Creating World Peace

GDUFA’s Impact on the API Industry

Orphan drugmaker ViroPharma attracts takeover interest

Teva, Sun Pharma to Pay $2.15 Billion to Settle Pfizer Patent Suit

After Tech Success, Israel Seeks Life Sciences Growth

EU to Fine Lundbeck, Others for Blocking Generic Drugs

Interview with Angelos Orfanos, DHL: Life Science Demands Advanced Infrastructure

India's Sun Pharma in Talks to Buy Sweden's Meda for $5-$6 Billion

Pfizer to Spin Off Zoetis Stake to Shareholders

Actavis to Buy Warner Chilcott in $5 Billion Stock Deal

Sanofi Fined in Plavix Generics Dispute

Drugmakers Face More Scrutiny of Discordant U.S. Prices

Teva Pharmaceutical Banks on Thrice-weekly Copaxone

Securing Product Supply in the Pharmaceutical Industry